Abstract:BACKGROUND:The peroxisome proliferator-activated receptor-γ (PPARγ) agonist rosiglitazone has been suggested to exert cardiovascular protection through the improvement of lipid metabolism, anti-inflammation, anti-proliferation etc. However, whether renin-angiotensin system (RAS) is involved in the vascular protective effects of PPARγ agonists is not fully understood. The present study aimed to investigate the effects of the renin-angiotensin system in vascular protection mediated by PPARγ agonists.OBJECTIVE:To investigate the actions of the renin-angiotensin system in vascular protection mediated by activation of PPARγ in vivo and in vitro.METHODS:Rats were fed a regular diet (n = 8), a cholesterol-rich diet plus methylthiouracil (80 mg/Kg/day, n = 10), a cholesterol-rich diet plus methylthiouracil and rosiglitazone (4 mg/kg/day, n = 10). The rosiglitazone treatment was started from one month after the start of cholesterol-rich diet plus methylthiouracil, and lasted five months. Cultured vascular smooth muscle cells (VSMCs) were pretreated with 1 μmol/L angiotensin II (ANG II) for 6 h and randomly divided into the control group; the ANG II group (1 μmol/L ANG II); the groups respectively treated with different concentration rosiglitazone (20, 30, 50) μmol/L for 12 h; the groups treated with 30 μmol/L rosiglitazone for (6, 12, 24) h. Morphology changes of the aortic tissues were observed by hematoxylin and eosin stain. The VSMC growth was detected by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric assay. Angiotensin II and expression of angiotensin receptors were determined by radioimmunoassay, reverse transcription polymerase chain reaction (RT-PCR), western blot, and immunohistochemistry.RESULTS:After 6 months, lipid deposition, VSMC proliferation and migration toward intima were observed in aortic tissues in the rats on a cholesterol-rich diet plus methylthiouracil, while these pathological changes induced by the cholesterol-rich diet were significantly suppressed by rosiglitazone. In addition, VSMC proliferation induced by ANG II was markedly inhibited by rosiglitazone. Rosiglitazone markedly down-regulated expression of angiotensin type 1 receptor (AT1R) and up-regulated expression of angiotensin type 2 receptor (AT2R) in the aortic tissues and ANG II-treated VSMCs.CONCLUSIONS:The present study demonstrated that PPARγ agonist rosiglitazone suppressed ANG II-induced VSMC proliferation in vitro and early atherosclerotic formation evoked by cholesterol-rich diet in vivo. These vasculoprotective effects of rosiglitazone were mediated at least partially by reduction in local tissue ANG II concentration, down-regulation of AT1R expression and up-regulation of AT2R expression both at the mRNA and protein levels.

[Inhibitory Effects of Rosiglitazone on Angiotensin II-induced Toll-Like Receptor 4 Expression and Myeloperoxidase Activity in RAW264.7 Cells].

Effects of Rosiglitazone on Serum Levels of Lipids and Inflammatory Factors in Atherosclerotic Rats

PPAR γ agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway

PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway.

PPARγ Agonist Rosiglitazone Ameliorates LPS-induced Inflammation in Vascular Smooth Muscle Cells Via the TLR4/TRIF/IRF3/IP-10 Signaling Pathway

Rosiglitazone Regulates C-reactive Protein–induced Inflammatory Responses Via Glucocorticoid Receptor–mediated Inhibition of P38 Mitogen-activated Protein Kinase–Toll-like Receptor 4 Signal Pathway in Vascular Smooth Muscle Cells

Inhibitory Effects of Rosiglitazone on Lipopolysaccharide-Induced Inflammation in a Murine Model and HK-2 Cells

Rosiglitazone inhibits angiotensin II-induced C-reactive protein production in human aortic endothelial cells through regulating AT 1 –ROS–MAPK signal pathway

Effect of rosiglitazone on the secretion of chemokines in renal tubular epithelial cells stimulated by lipopolysaccharide and the possible mechanism

Effects of Rosiglitazone on the Expression of Angiotensin Ⅱ Type 1 Receptor and Type 2 Receptor in Angiotensin Ⅱ-Induced Mice Vascular Smooth Muscle Cells

Rosiglitazone Attenuates Angiotensin II-induced C-reactive Protein Expression in Hepatocytes Via Inhibiting AT1/ROS/MAPK Signal Pathway.

Inhibitory Effects of Rosiglitazone on the Synthesis of Reactive Oxygen Species and the Expression of Monocyte Ehemoattractant Protein 1 in Rat Mesangial Cells Cultured in High Glucose

Rosiglitazone Impedes Porphyromonas Gingivalis-Accelerated Atherosclerosis by Downregulating the TLR/NF-κB Signaling Pathway in Atherosclerotic Mice

Vasculoprotective Effects of Rosiglitazone Through Modulating Renin-Angiotensin System in Vivo and Vitro.

Rosiglitazone Inhibitory Effect on Mesangial Cell Proliferation and Extracellular Matrix Expression Induced by Angiotensin Ⅱ

Rosiglitazone Inhibits Angiotensin II-induced CTGF Expression in Vascular Smooth Muscle Cells––role of PPAR-γ in Vascular Fibrosis

The PPARγ Agonist, Rosiglitazone, Attenuates Airway Inflammation and Remodeling Via Heme Oxygenase-1 in Murine Model of Asthma

Effect of PPARγ Agonist (rosiglitazone) on the Secretion of Th2 Cytokine in Asthma Mice.

[Angiotensin II Induces Toll-Like Receptor 4 Expression and Myeloperoxidase Activity in RAW264.7 Cells].

Effects of rosiglitazone on rat aortic adventitial fibroblasts migration induced by angiotensinⅡ

Rosiglitazone Attenuates Allergic Inflammation and Inhibits Expression of Galectin-3 in a Mouse Model of Allergic Rhinitis